SG Americas Securities
MLTX icon

SG Americas Securities’s MoonLake Immunotherapeutics MLTX Stock Holding History

SG Americas Securities’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
9,350
-12,538
-57% -$208K ﹤0.01% 2705
2025
Q4 		$288K Buy
21,888
+4,362
+25% +$51.5K ﹤0.01% 2770
2025
Q3 		$126K Buy
+17,526
New +$913K ﹤0.01% 2984
2024
Q2 		– Sell
-14,458
Closed -$726K – 3129
2024
Q1 		$726K Buy
+14,458
New +$784K ﹤0.01% 1274

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities's MLTX Position: Q1 2026 in Review

SG Americas Securities reduced its MoonLake Immunotherapeutics (MLTX) stake by 57% in Q1 2026, selling an estimated $208K and leaving 9,350 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #2705.

SG Americas Securities first reported a position in MLTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $726K in Q1 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • SG Americas Securities held 9,350 shares of MoonLake Immunotherapeutics worth $174K as of Q1 2026.
  • SG Americas Securities sold 12,538 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $208K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2705 holding.
  • SG Americas Securities first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 4 quarters since.
  • SG Americas Securities's MoonLake Immunotherapeutics position peaked at $726K in Q1 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.